FOXA vs MLTX · P/E 14, rev $17.13B vs $1.41B cap
Fox Corp Class A (FOXA) versus MoonLake Immunotherapeutics (MLTX) — a side-by-side from cached financials, not a winner call.
Fox Corp Class A (FOXA) is a entertainment company listed on US.
MoonLake Immunotherapeutics (MLTX) is a biotechnology company listed on US.
Latest reported FOXA revenue for 2026-06-30 was $17.13B. Net income was $1.73B. Revenue was up 5.1% from 2025-06-30 to 2026-06-30. FOXA currently screens at market cap $24.50B and trailing P/E 14.1.
MLTX does not have a complete income-statement cache yet.
FOXA currently screens at market cap $24.50B and trailing P/E 14.1. MLTX currently screens at market cap $1.41B.
Not investment advice. Open the FOXA and MLTX stock pages for the full models.
Not investment advice.